drugset / Trial / NCT06246799
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
Phase 3
Recruiting
256 enrolled
The University of Texas Health Science Center at San Antonio
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupOpen-labelOther
Summary
The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.
Timeline
- Start
- 2024-11-07
- Primary completion
- 2029-04-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metformin | Small molecule | 2000 mg | — |
| Subject | Pioglitazone | Small molecule | 45 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |
| Subject | Tirzepatide | Peptide | 15 mg | — |